FTC Approves the Pfizer-Wyeth Deal And Keeps Their Human Drug Portfolio Intact

The FTC requires Pfizer to divest half of Wyeth's animal health business but finds their human drug products, particularly for Alzheimer's disease and osteoporosis, do not compete with each other.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet